A comprehensive, multi-center, immunogenomic analysis of melanoma brain metastases
Lucy Boyce Kennedy(Cleveland Clinic), April K.S. Salama(Duke University), Carey K. Anders(Duke University), Dadong Zhang(Precision for Medicine (United States)), Alexander B. Sibley(Duke University), Marissa R. Lee(Duke University), Kouros Owzar(Duke University), Swaminathan Kumar(The University of Texas MD Anderson Cancer Center), Amanda E.D. Van Swearingen(Duke Cancer Institute), Eric Lipp(Duke Medical Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Jeff Sheng(Duke Medical Center), Layne W. Rogers(Duke University), Pixu Shi(University of Pittsburgh), Aron Y. Joon(The University of Texas MD Anderson Cancer Center), Xiaodi Qin(Duke Cancer Institute)
Cited by 2
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k